Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CapeOx + Tislelizumab + Dihydroartemisinin for MSS Locally Advanced and Metastatic Colorectal Cancer
NCT07801352Phase 2Active, not recruiting
- Sponsor
- Shanghai Changzheng Hospital
- Start
- Jul 2024
- Primary completion
- Jul 2025
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab, dihydroartemisinin in colorectal cancer (CRC), sponsored by Shanghai Changzheng Hospital. Started Jul 2024; status: active, not recruiting.
02
Drugs
tislelizumabdihydroartemisinin
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07801352.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07801352.